Delivery Order SPE2DP20D0002-SPE2DP25F054S
Award Date 8/12/25
Potential Completion Date 8/26/25
Potential Value $661K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Teva Pharmaceuticals USA, Inc. was awarded a delivery order valued at $825,784.65 for Adenovirus Type 4 vaccine by the Defense Logistics Agency's Medical Supply Chain division on September 8, 2025, with an ultimate completion date of September 23, 2025. The contract is structured as a firm-fixed-price delivery order with no set-aside designation, indicating Teva competed as a large business in an unrestricted solicitation. Performance will take place at Teva's facility in Parsippany, New Jersey....
- The U.S. Department of Defense, through the Defense Logistics Agency Troop Support Medical, awarded a delivery order valued at $330,313.86 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine. The contract, awarded on July 14, 2025, with a completion date of July 29, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will be conducted at Teva's facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's...
- Teva Pharmaceuticals USA, Inc. was awarded a $660,627.72 firm fixed-price delivery order for Adenovirus Type 4 vaccine, with an ultimate completion date of July 29, 2025. This contract, issued by the Medical Supply Chain division within the Department of Defense, represents a non-set-aside award structured as a delivery order under what appears to be a larger indefinite delivery contract vehicle. The work will be performed in Parsippany, New Jersey, where Teva maintains its primary manufacturing...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $825,784.65 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, and performance will be executed at Teva's facility in Parsippany, New Jersey. This delivery order is issued under a larger indefinite delivery vehicle and...
- The U.S. Department of Defense's Medical Supply Chain awarded Teva Pharmaceuticals USA, Inc. a $165,156.93 firm fixed-price delivery order for Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This delivery order, issued December 1, 2025, represents a continuation of Teva's critical role as a primary supplier under an existing indefinite delivery contract vehicle with the Defense Logistics Agency Troop Support Medical. The award carries no set-aside designation and...
- Teva Pharmaceuticals USA, Inc. has been awarded a $1,526,969 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to supply adenovirus type 4 vaccine. This delivery order was issued under an existing contract vehicle and will support the immunization programs of the military. Teva will deliver the vaccine products to the agency's location in Parsippany, New Jersey by December 19, 2023. As a major pharmaceutical manufacturer, Teva has extensive experience...
- Teva Pharmaceuticals USA, Inc., headquartered in Parsippany, New Jersey, has been awarded a delivery order valued at $660,627.72 for the supply of Adenovirus Type 4 vaccine to support critical military immunization programs. This firm-fixed-price delivery order, issued without set-aside designation, carries an ultimate completion date of December 9, 2025, just over one week from the award date of December 1, 2025. The contract is funded through the Medical Supply Chain, a defense-focused federal...
- Teva Pharmaceuticals USA, Inc. has been awarded a firm fixed-price delivery order valued at $330,313.86 for Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. The contract, issued without set-aside designation by the Defense Logistics Agency Troop Support Medical on December 1, 2025, will be performed at Teva's facility in Parsippany, New Jersey. This delivery order represents one of over 150 similar awards issued to Teva since 2023, positioning the company as a...
- Teva Pharmaceuticals USA, Inc. has been awarded a $305,393.76 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to provide adenovirus type 4 vaccine. Performance will take place in Parsippany, New Jersey through December 2023. This delivery order was issued against an existing contract vehicle and supports the immunization programs of the military. Teva Pharmaceuticals has a history of partnering with subcontractors and receiving contract awards to supply...
- The Department of Defense's Medical Supply Chain awarded a $165,156.93 delivery order to Teva Pharmaceuticals USA, Inc. on December 1, 2025, for the supply of Adenovirus Type 4 vaccine. This firm-fixed-price delivery order, with an ultimate completion date of December 9, 2025, represents part of Teva's extensive portfolio supporting critical military immunization programs. The contract contains no set-aside designation and will be performed at Teva's manufacturing facility in Parsippany, New...